Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:44:52 10/05/2024 am IST			5-day change	1st Jan Change
4.205 ^USD	+2.31%		+1.82%	-35.02%

06:01pm	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
08/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	MT

Autolus Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:30 pm IST

Autolus Therapeutics plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 208.38 million compared to USD 148.84 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 1.57 a year ago.

Latest news about Autolus Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09:31pm	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	25/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19/04	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	18/04	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11/04	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	08/04	MT
European Equities Close Lower Tuesday; Eurozone Manufacturing at 3-Month Low; Mining Stocks Rally, Real Estate Drops	02/04	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	02/04	MT
Autolus Therapeutics Gets European Agency Approval for Marketing Authorization Application for Leukemia Treatment	02/04	MT
Autolus Therapeutics Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02/04	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02/04	AN
Autolus Therapeutics Appoints Mike Bonney as Chair	01/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	01/04	MT
Autolus Therapeutics Announces Changes to its Board of Directors	01/04	CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	27/03	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	20/03	MT
Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating	18/03	MT
Autolus Therapeutics plc Announces Resignation of Edgar Braendle, Chief Development Officer	14/03	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	14/03	MT
Syncona portfolio company Autolus posts widened loss for 2023	14/03	AN
Transcript : Autolus Therapeutics plc, 2023 Earnings Call, Mar 14, 2024	14/03

Chart Autolus Therapeutics plc

Duration

Period

More charts

Company Profile

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Autolus Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.11 USD

Average target price

10.54 USD

Spread / Average Target

+156.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AUTOLUS THERAPEUTICS PLC	-35.02%	1.09B
VERTEX PHARMACEUTICALS INCORPORATED	+3.05%	108B
REGENERON PHARMACEUTICALS, INC.	+10.37%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.63%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-7.17%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.34%	13.99B
SAREPTA THERAPEUTICS, INC.	+38.21%	12.53B

Bio Therapeutic Drugs